Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 800-636-0373.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
Participating specialty pharmacies must complete a 1-time registration so they may process ENSPRYNG Co-pay Program* payments. To register, call (800) 636-0373.
*Eligible commercially insured patients who are prescribed ENSPRYNG for an FDA-approved use can receive up to $20,000 in assistance per 12-month period.
ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis.
Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live attenuated vaccines is not recommended during treatment.
Elevated Liver Enzymes
Monitor ALT and AST levels during treatment; interruption of ENSPRYNG may be required.
Decreased Neutrophil Counts
Monitor neutrophils during treatment.
The most common adverse reactions (≥15% in either trial) were nasopharyngitis (31%), headache (27%), upper respiratory tract infection (19%), rash (17%), arthralgia (17%), extremity pain (15%), gastritis (15%), fatigue (15%), and nausea (15%).